Hydrolyzed moabi press cake, preparation process and use in cosmetics, particularly for treating skin aging and depigmenting the skin

A hydrolyzate of moabi cake, produced via alkaline hydrolysis, addresses intrinsic skin aging by enhancing skin hydration, elasticity, and depigmentation, offering a stable and effective cosmetic solution for improving skin appearance.

FR3132845B1Active Publication Date: 2024-11-29LEWAI LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
FR2022001611
Authority / Receiving Office
FR · FR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-02-23
Publication Date
2024-11-29
Estimated Expiration
2042-02-23

AI Technical Summary

Technical Problem

There is a need for new cosmetic compositions that provide moisturizing, anti-aging, and depigmenting properties to address intrinsic skin aging, which is characterized by a loss of elasticity, skin barrier alteration, and the appearance of wrinkles and dark spots due to melanin concentration, and there is a lack of effective valorization of moabi cake by-products.

Method used

A hydrolyzate of moabi cake is produced through an alkaline hydrolysis process, comprising proteins, sugars, and polyphenols, which is incorporated into cosmetic compositions to enhance skin hydration, elasticity, and depigmentation.

Benefits of technology

The hydrolyzate improves skin firmness, reduces wrinkles, hydrates the skin, and effectively depigments and lightens the skin, while being non-irritating and stable, with visible improvements in skin appearance and comfort.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Hydrolysate of moabi press cake comprising 0.50 to 1.50% by weight of proteins, 0.50 to 2.00% by weight of sugars, and 1.5 to 3.0 ppm of polyphenols relative to the total weight of the hydrolysate; preparation process; cosmetic and non-therapeutic compositions; and cosmetic uses, particularly as a moisturizing agent, for preventing and / or treating signs of skin aging, and for whitening, lightening, and / or depigmenting the skin. Figure to be published with the abbreviation: Fig. 1
Need to check novelty before this filing date? Find Prior Art

Description

Title of the invention: Moabi cake hydrolyzate, preparation process and use in cosmetics, in particular for treating skin aging and depigmenting the skin

[0001] The present invention relates to the field of the valorization of moabi cake. More specifically, the invention relates to an extract of hydrolyzed moabi cake as well as its use in cosmetics, in particular as an agent for preventing and / or treating the signs of skin aging, for moisturizing the skin and for whitening, lightening and / or depigmenting the skin.

[0002] The skin is the main protective barrier of the human body against external aggressions such as atmospheric pollution, climatic variations and UV radiation.

[0003] The skin is made up of three layers: the epidermis, the dermis and the hypodermis. The epidermis, which is in contact with the outside world, is particularly affected by external aggressions. The epidermis is covered by a hydrolipidic film and is made up of four layers: the stratum corneum, the granular layer, the spinous layer and the basal layer. The skin, and in particular the epidermis, is thus constantly subjected to stresses which cause it to age.

[0004] A distinction is generally made between intrinsic aging and extrinsic aging.

[0005] Intrinsic aging, also called physiological aging, causes a slowdown in the renewal of keratinocytes, which are the cells of the superficial layers of the skin, particularly the epidermis. The reduction of subcutaneous fatty tissue and the appearance of fine wrinkles are the main manifestations of intrinsic aging.

[0006] Extrinsic aging is characterized by a loss of skin elasticity, an alteration of the skin's barrier function and the appearance of deep wrinkles. Extrinsic aging is mainly due to repeated exposure of the skin to the sun, it is also associated with the appearance of darker spots which generate areas of non-uniform appearance. This aging is also called photoaging or actinic aging.

[0007] The present invention relates more particularly to intrinsic aging.

[0008] These dark spots are generally due to a localized concentration of melanin on the surface of the skin. Melanin is the pigment that causes skin color and is produced by melanocytes located in the epidermis.

[0009] The mechanism of formation of skin pigmentation, i.e. of the melanin, is particularly complex and schematically involves the following main stages, at the level of the melanocytes of the basal layer:

[0010] Tyrosine —» DOPA —» Dopaquinone —» Leucodopachrome —» Dopachrome —» M elanine

[0011] Tyrosinase (monophenol dihydroxyl phenylalanine: oxygen oxidoreductase EC 1.14.18.1) is the essential enzyme involved in this series of reactions. In particular, it catalyzes the reaction of transformation of tyrosine into Dopa (dihydroxyphenylalanine) thanks to its hydroxylase activity and the reaction of transformation of Dopa into dopaquinone thanks to its oxidase activity.

[0012] There therefore remains a need for new cosmetic compositions intended to be applied to the skin and which have moisturizing, anti-aging and depigmenting properties.

[0013] The inventors have shown that a solution to this technical problem could be provided by means of a particular extract of moabi cake.

[0014] Moabi or Baillonella toxisperma is a plant species in the Sapotaceae family. Moabi is a large tree growing in the tropical rainforests of Africa. It is traditionally exploited as a tropical timber. The seeds of moabi fruits are traditionally pressed to obtain an oil used in the local cosmetic industry.

[0015] Moabi oil, obtained by pressing and then refining to a greater or lesser extent, generates a large quantity of solid by-products called moabi cakes.

[0016] There is still a need to find new ways of valorizing high added value moabi cake.

[0017] Surprisingly and advantageously, the inventors have demonstrated a particular extract of moabi cake obtained by a particularly innovative alkaline hydrolysis process in the treatment of moabi cake, and presenting advantageous effects in cosmetics when applied to the skin, more particularly cosmetic properties, notably moisturizing, anti-aging and depigmenting.

[0018] The subject of the present invention is a moabi cake hydrolysate comprising from 0.50 to 1.50% by weight, preferably 0.83% by weight, of proteins relative to the total weight of the hydrolysate; from 0.50 to 2.00% by weight, preferably 1.19% by weight, of sugars relative to the total weight of the hydrolysate and from 15 to 30 ppm, preferably 23 ppm, of polyphenols relative to the total weight of the hydrolysate.

[0019] Advantageously, said moabi cake hydrolyzate is such that its visible UV spectrum has a peak at an X wavelength of 230 nm for an absorbance of 2.262.

[0020] In this text, the hydrolyzate is also called moabi cake extract or hydrolyzed moabi cake extract.

[0021] The present invention also relates to a process for preparing the hydrolyzate according to the invention comprising at least the following steps, in this order: - provide moabi seeds; - defat the moabi seeds and recover the cake; - place the moabi cake in aqueous phase; - subjecting the cake to at least one hydrolysis step using an alkaline solution at a pH ranging from 13 to 14 for a period ranging from 30 minutes to 4 hours, - adding a weak acid so as to adjust the pH to a value ranging from 4.5 to 5.5; - carrying out a solid / liquid separation, - recovering the hydrolysate obtained.

[0022] Advantageously, during hydrolysis, the ratio of mass of moabi cake / mass of alkaline solution is between 1 / 12 and 1 / 8 and preferably approximately 1 / 10.

[0023] The present invention also relates to a non-therapeutic cosmetic composition comprising at least one hydrolyzate according to the present invention or prepared according to the process according to the present invention, preferably in a content ranging from 0.001 to 30% by weight and preferably from 0.1 to 20% by weight relative to the total weight of the composition.

[0024] According to a particular variant, the non-therapeutic cosmetic composition comprises a moabi cake hydrolyzate according to the present invention and ascorbyl tetraisopalmitate, preferably according to an ascorbyl tetraisopalmitate / hydrolyzate ratio ranging from 1 / 1 to 1 / 10 and advantageously approximately 1 / 3.

[0025] The hydrolyzate according to the invention makes it possible to provide a product containing several types of active ingredients of interest in cosmetics, i.e. proteins, sugars and polyphenols.

[0026] Thus, the moabi cake hydrolyzate and the cosmetic composition according to the invention advantageously make it possible to prevent and / or reduce the signs of skin aging, in particular the loss of elasticity of the skin, the alteration of the barrier function of the skin, the appearance of wrinkles and / or fine lines. It has been observed that the treated skin is firmer.

[0027] The moabi cake hydrolyzate and the cosmetic composition according to the invention also make it possible to whiten and / or lighten and / or depigment the skin of the face and / or body in a lasting manner. They also make it possible to reduce the size of brown pigment spots and therefore to make specific areas of the face and / or body more homogeneous.

[0028] It has also been observed that treated skin is hydrated, plumped up, it appears brighter, more radiant, softer, more supple. Treated skin is less dry, less dull.

[0029] These cosmetic compositions are furthermore stable, non-irritating, non-sensitizing reading, non-toxic, in particular non-phototoxic, non-allergenic for the skin.

[0030] The moabi cake hydrolyzate and the cosmetic composition according to the invention provide an improvement in the overall appearance of the skin as well as a feeling of comfort.

[0031] Other aspects, advantages, properties of the present invention are presented in the description and examples which follow.

[0032] Definitions

[0033] In this text, unless specifically indicated otherwise, the percentages are expressed by weight of a reference composition.

[0034] In this text, intervals are defined in abbreviated form in order to avoid describing each and every value in that interval, however any suitable value in the interval may be chosen as the upper value, the lower value or the terminal values ​​of the interval. For example, an interval from 0.1 to 1.0 represents the terminal values ​​of 0.1 and 1.0, as well as the intermediate values ​​of 0.2; 0.3; 0.4; 0.5; 0.6; 0.7; 0.8; 0.9 and all intermediate intervals within 0.1 to 1.0, such as 0.2 to 0.5; 0.2 to 0.8; 0.7 to 1.0... An interval defined as "between value A and value B" includes values ​​A and B and is therefore equivalent to an interval "from value A to value B". Furthermore, the expression "at least" includes the value stated after, for example, "at least 5%" should be understood as also including "5%".The expression "a maximum of" includes the value stated after, for example, "a maximum of 5%" should be understood as also including "5%".

[0035] Furthermore, in the present text, measurable values, such as a quantity, are to be understood as including standard deviations that can be readily determined by a person skilled in the art in the reference technical field. Preferably, these values ​​are intended to include variations of ± 5%.

[0036] In this text, the singular form of a word includes the plural and vice versa, unless the context clearly indicates otherwise. Thus, the references "a", "an" and "the" generally include the plurals of the respective terms. For example, a reference to a "process" or a "composition" includes a plurality of such "processes" or "compositions". In particular, in this text, the terms "moabi cake" and "moabi cakes" are used interchangeably.

[0037] By “skin” we mean the epidermis of the face or body and in particular the face, neck, décolleté and hands.

[0038] The expressions “bleaching”, “lightening” and “depigmentation” used to define the properties of the compositions according to the invention have the same meaning, as do the expressions “bleach”, “lighten” and “depigment”.

[0039] By "prevent" or "prevention" we mean the fact of reducing, at least in part, the risk of an effect occurring.

[0040] The compositions and methods used according to the present invention are cosmetic, not therapeutic.

[0041] These compositions are intended to be applied to healthy skin, by simple massage to treat the epidermis. They comply with EC regulation 1223 / 2009. Figures

[0042] [Fig.l] corresponds to the UV-Visible spectrum of the hydrolyzate according to the invention prepared in Example 1 after dilution of the sample to 1 / 100th in demineralized water and obtained using a Jenway® 6705 UV-Visible spectrometer.

[0043] [Fig.2] corresponds to the results of the melanic indices, in average values, between D1 and D28 for the different areas studied: treated pigmented area, treated non-pigmented area, untreated non-pigmented area in the study of the depigmenting cosmetic composition according to the invention presented in example 3.

[0044] Hydrolyzate

[0045] The hydrolyzate according to the present invention is prepared from moabi or Baillonella toxisperma seed cakes.

[0046] It is known that moabi seeds are used for the extraction of their oil, useful for self-consumption or in various traditional medicinal treatments. The cake obtained after defatting (deoiling) the seed is a waste product that is currently little used.

[0047] According to a preferred embodiment, the hydrolyzate according to the invention is obtained from the cake of hulled moabi seeds.

[0048] According to the present invention, the moabi cakes are recovered after extraction of the oil from the seeds and then hydrolyzed.

[0049] The hydrolyzate according to the invention comprises from 0.50 to 1.50% by weight, preferably 0.83% by weight, of proteins relative to the total weight of the hydrolyzate, from 0.50 to 2.00% by weight, preferably 1.19% by weight, of sugars relative to the total weight of the hydrolyzate and from 15 to 30 ppm, preferably 23 ppm, of polyphenols relative to the total weight of the hydrolyzate.

[0050] Process for preparing the hydrolyzate

[0051] As already mentioned, the process for preparing moabi cake hydrolysate comprises at least the following steps, in this order: - provide moabi seeds; - defat the moabi seeds and recover the cake; - place the moabi cake in aqueous phase; - subject the cake to at least one hydrolysis step using a solution alkaline at a pH ranging from 13 to 14 for a period ranging from 30 minutes to 4 hours, - add a weak acid so as to adjust the pH to a value ranging from 4.5 to 5.5; - carry out a solid / liquid separation, - recover the hydrolyzate obtained.

[0052] Generally, the seeds intended to be used in the process according to the invention are hulled, that is to say the kernel is used.

[0053] The moabi cake used in the process according to the invention is obtained after defatting the moabi seeds, preferably the moabi kernels. This step aims to extract the oil from the moabi seeds.

[0054] Defatting can be carried out by mechanical pressing of the seeds or by extraction using a non-polar organic solvent, for example hexane.

[0055] Preferably the seeds, possibly in the form of almonds, are dried or left to dry so as to obtain a humidity level of less than 7%.

[0056] Then they are subjected to defatting in order to separate the oil from the rest of the seed and to obtain the cake. Generally the cake comprises less than 5% by weight of oil, called "residual oil", relative to the total weight of the cake.

[0057] According to a preferred variant, the cake is then mechanically ground with any type of mechanical grinders such as hammer, flail, knife, crushing / shredding, ball or peal systems, but also with any type of cryogrinder.

[0058] Grinding the cake advantageously makes it possible to obtain the appropriate particle size. By "size" is meant the length of the largest dimension of the particles. Generally, moabi cake particles have a maximum size close to 5 mm, preferably close to 3 mm, and more preferably between 1 and 2 mm.

[0059] The cake, advantageously ground, is then dispersed in aqueous phase.

[0060] The moabi cake hydrolysate according to the present invention is obtained by hydrolysis using an alkaline solution at a pH ranging from 13 to 14, preferably obtained using a strong base.

[0061] The strong base is generally chosen from sodium hydroxide (NaOH), potassium hydroxide (KOH) and calcium hydroxide (CaOH); preferably sodium hydroxide. Advantageously, the strong base solution has a molarity of between 0.8 M and 1.5 M.

[0062] The alkaline hydrolysis is carried out using an alkaline solution at a pH ranging from 13 to 14 for a period ranging from 30 minutes to 4 hours, preferably for approximately 2 hours.

[0063] The alkaline hydrolysis is carried out at a temperature ranging from 12 to 40°C, preferably at room temperature, i.e. between 15 and 25°C.

[0064] Furthermore, the ratio of mass of moabi cake / mass of the alkaline solution is advantageously between 1 / 12 and 1 / 8 and preferably approximately 1 / 10.

[0065] The dispersion in aqueous phase and the alkaline hydrolysis are advantageously carried out with stirring, thus allowing dispersion and homogenization of the solid in the liquid, thus improving the overall exchange surface and consequently the hydrolysis.

[0066] After the hydrolysis step, an acid, preferably a weak organic acid, is added to “neutralize” the solution, i.e. to adjust the pH to a value ranging from 4 to 5 and consequently stabilize the hydrolyzate obtained.

[0067] The weak acid is preferably chosen from citric acid, phosphoric acid, lactic acid, oxalic acid, acetic acid, acetic acid, glycolic acid, ascorbic acid and mixtures thereof, preferably citric acid. Weak acids, in particular citric and phosphoric, also make it possible to generate a pH buffer effect sought in cosmetic compositions.

[0068] After recovery of the hydrolyzate by solid / liquid separation, i.e. recovery of the liquid phase, the hydrolyzate is advantageously purified by filtration or ultrafiltration.

[0069] Finally, lyophilization of the hydrolyzate can also be carried out in order to have said hydrolyzate in solid form.

[0070] The method according to the invention may also comprise conventional purification and spinning steps, the implementation of which falls within the skills of a person skilled in the art.

[0071] Composition

[0072] As already mentioned, the present invention also relates to a cosmetic composition, comprising the moabi cake hydrolyzate according to the present invention.

[0073] Advantageously, the composition according to the present invention comprises from 0.001 to 30% by weight and preferably from 0.1 to 20% by weight of moabi cake hydrolyzate relative to the total weight of the composition.

[0074] Advantageously, the non-therapeutic cosmetic composition according to the present invention comprises, in a cosmetically acceptable medium, at least one cosmetic agent chosen from humectants, thickeners, texturizing agents, emulsifiers, dispersing agents, foaming agents, emulients, preservatives, colorants, plant extracts, plant fibers, minerals, pH correcting agents, active ingredients and perfumes.

[0075] Advantageously, the cosmetic composition according to the present invention comprises from 0.001 to 20% by weight of at least one cosmetic agent relative to the total weight of the composition.

[0076] Of course, the person skilled in the art will take care to choose these cosmetic agents of so as not to alter the properties of the composition according to the invention.

[0077] The composition according to the invention can be presented in all the galenic forms normally used in the cosmetic field, and in particular in the form of a powder or lozenge, in particular a toothpaste lozenge, a syndet, in particular a solid shampoo, an aqueous or hydroalcoholic solution, optionally gelled, optionally foaming, a dispersion of the lotion type, optionally two-phase, an oil-in-water or water-in-oil or multiple emulsion (W / O / W or O / W / O for example), an aqueous gel, a dispersion of oil in an aqueous phase using spherules, these spherules being able to be polymeric nanoparticles such as nanospheres and nanocapsules or, better, lipid vesicles of ionic and / or non-ionic type; of aqueous or oily gel. These compositions are prepared according to the usual methods.

[0078] The composition according to the invention may constitute a skin care composition, and in particular a cleansing, protective, treatment or care cream for the mouth, the face, for the hands, for the feet, or for the body, in particular the composition may be a day cream, night cream, make-up remover cream, foundation cream, sunscreen cream; a fluid foundation, a make-up remover milk, a protective or care body milk, an anti-sunscreen milk; a lotion, gel or mousse for skin care, such as a cleansing lotion.

[0079] Advantageously, the cosmetic composition according to the present invention comprises ascorbyl tetraisopalmitate also called Vitamin C tetra E. Preferably the ascorbyl tetraisopalmitate / hydrolyzate ratio ranges from 1 / 1 to 1 / 10 and advantageously approximately 1 / 3.

[0080] Advantageously, the cosmetic composition according to the present invention comprises from 0.001 to 20% by weight of ascorbyl tetraisopalmitate relative to the total weight of the composition.

[0081] The composition according to the invention comprising ascorbyl tetraisopalmitate is particularly advantageous for its lightening and depigmenting properties.

[0082] The composition according to the invention is advantageously intended to be applied to the skin.

[0083] The cosmetic composition according to the present invention is advantageously used in topical application to the skin as a skin whitening and / or lightening and / or skin depigmenting agent, as well as an anti-aging agent for the skin.

[0084] Uses

[0085] The present invention also relates to the cosmetic, non-therapeutic use of at least one hydrolyzate according to the invention or prepared according to the invention or even of at least one cosmetic composition according to the present invention as a moisturizing active ingredient for the skin.

[0086] The present invention also relates to the cosmetic, non-therapeutic use of at least one hydrolyzate according to the invention or prepared according to the invention or even of at least one cosmetic composition according to the present invention as an active ingredient for preventing and / or reducing the signs of skin aging, in particular the loss of elasticity of the skin, the alteration of the barrier function of the skin, the appearance of wrinkles and / or fine lines.

[0087] The present invention also relates to the cosmetic, non-therapeutic use of at least one hydrolyzate according to the invention or prepared according to the invention or even of at least one cosmetic composition according to the present invention as an active ingredient for whitening and / or lightening and / or depigmenting the skin, in particular for reducing the size of brown pigmentation spots, attenuating or even eliminating brown pigmentation spots, or even preventing, reducing and / or treating an alteration in the complexion of the skin.

[0088] More particularly, said use makes it possible to reduce, attenuate, eliminate pigmentation defects of the skin.

[0089] The present invention also relates to a cosmetic, non-therapeutic process for treating the skin, comprising at least one step of applying to the skin at least one hydrolyzate according to the invention or prepared according to the invention or even at least one cosmetic composition according to the present invention.

[0090] According to a first variant, the method is a cosmetic, non-therapeutic treatment method intended to maintain or improve the hydration of the skin.

[0091] According to a second variant, the method is a cosmetic, non-therapeutic method intended to prevent and / or reduce the signs of skin aging, in particular the loss of elasticity of the skin, the alteration of the barrier function of the skin, the appearance of wrinkles and / or fine lines.

[0092] According to a third variant, the process is a cosmetic, non-therapeutic process intended to depigment, lighten and / or whiten the skin.

[0093] The following examples are intended to illustrate the invention without limiting its scope.

[0094] Examples

[0095] Example 1- Hydrolyzed moabi cake extract

[0096] I. Preparation of the hydrolyzate

[0097] An alkaline solution is prepared by mixing 84 g of 1 M sodium hydroxide and 2017 g of water in a 3 liter reactor / hydrolyzer equipped with a 4-blade propeller mixer (IKA RW20 stirrer).

[0098] 210 g of moabi cake, previously ground with a knife mill (SM 100 RETSCH) and previously defatted with 2.4 L of hexane, are introduced into the reactor.

[0099] The mixture is kept stirring for 2 hours at room temperature.

[0100] At the end of these 2 hours, 178.5 g of citric acid monohydrate are added and Stirring is maintained until the acid is completely dissolved. The pH is measured and is equal to 5.12.

[0101] Then 10.5 g of sodium benzoate are added, as a preservative, and stirring is continued until the sodium benzoate is completely dissolved. The pH is measured; it is equal to 5.15. After decantation, the mixture was filtered through a pleated filter.

[0102] 1689g of filtrate are obtained, i.e. a yield of 68% by weight.

[0103] II. Determination of the composition of the hydrolyzed moabi extract

[0104] A. Analysis of the protein content of the hydrolyzed extract by the Lowry method

[0105] The amount of total protein was determined by colorimetric assay according to the Lowry method. For this colorimetric assay, a standard curve of optical density, called OD in the rest of the text, measured at 750 nm, as a function of the amount of protein was produced. The reference protein used in this experiment is bovine serum albumin (BSA).

[0106] This method, well known to those skilled in the art, is described in particular in “Protein measurement with the Folin phenol reagent”, Oliver H. Lowry, Nira J. Rosebrough, A. Lewis Farr and Rose J. Randall, J. biol. Chem., vol. 193, no. 1, 1951, pp. 265-275.

[0107] Then the total quantity of proteins in each sample of hydrolysate to be tested was determined by preparing several copies of the sample to be tested according to the same protocol as that used for the standard range and then by reporting the OD values ​​obtained for the samples to be tested on the standard curve.

[0108] Preparation of the standard range

[0109] The ingredients for preparing the standard range were as follows: BSA: Bovine serum albumin marketed by Sigma Aldrich ®; SDS: sodium dodecyl sulfate 20% marketed by Biosolve ®; Water: WATER PLUS marketed by Carlo Erba ®; Na2CO3, NaOH IM, CuSO4, Na / K Tartrate and Folin-Ciocalteu reagent marketed by Carlo Erba ®; DMSO marketed by Sigma Aldrich ®.

[0110] The following solutions were prepared: 0.1% SDS: Dilution of 1 mL of the 20% (m / v) stock solution in 200 mL (final volume) of WATER PLUS water; BSA at 2 mg / mL: solubilization of 2 mg of BSA in 1 ml of WATER PLUS water; BSA at 0.2 mg / ml: dilution of 100 pL of the BSA solution at 2 mg / mL in ImL (final volume) of WATER PLUS water; NaOH 0.1 M: dilution of 5 mL of IM NaOH in 50 mL (final volume) of WATER PLUS water; Reagent A: Na2CO3 20g / L, NaOH 0.1M: Solubilization of 1g of Na2CO3 in 50mL of 0.1M NaOH; Reagent B: CuSO4 5g / l, Na / K Tartrate 10g / L: Solubilization of 25mg of CuSO4 and 50mg of Na / K Tartrate in 5mL of WATER PLUS water. The mixture is kept in the dark; Reagent C: 1 mL of Reagent B is added to 50 mL of Reagent A. The mixture is kept in the dark; Reagent D (Diluted Folin-Ciocalteu Reagent): Dilution of 5 mL of commercial Folin-Ciocalteu reagent in 5 mL of WATER PLUS. The mixture is kept in the dark.

[0111] The standard range was carried out in three copies (triplicate), the compositions forming the standard range are presented in table 1.

[0112] [Tables 1] Tube No. 1 2 3 4 5 6 7 Amount of BSA (pg) 0 2.5 5 10 15 20 25 SDS 0.1% (pL) 150 137.5 125 100 75 50 25 Reagent C (pL) 750 Reagent D (pL) 75

[0113] Preparation of the standard range

[0114] The amounts of BSA, SDS and reagent C indicated in Table 1 above were introduced into tubes 1 to 7 and then the tubes were mixed by inversion. After a 10-minute break in the dark, 75 μL of reagent D was added to each tube. Then the tubes were mixed again by inversion. After a 30-minute break in the dark, absorbance measurements at 750 nm were carried out.

[0115] The OD measurements at 750 nm were carried out using a “Genesys 150” spectrophotometer from ThermoFisher Scientific.

[0116] The DO measurements at 750 nm made it possible to define a curve with the equation: y = 0.0178x with R2 = 0.9904.

[0117] Preparation of samples to be measured

[0118] Then the samples to be measured were prepared according to the following protocol: several samples of the sample to be tested were introduced into test wells and they were diluted 1 / 100 in 0.1% SDS for a total volume of 150 pL. Then 750 pL of reagent C was added to each test well. The test wells were mixed by inversion. After a 10-minute break in the dark, 75 pL of reagent D was added to each test well. Then the wells were mixed again by reversal, after a 30-minute break in the dark, absorbance measurements at 750 nm are carried out.

[0119] Table 2 presents the results obtained for a dilution of the samples equal to 100. From the standard curve, the protein concentration of each sample was determined.

[0120] [Tables2] Tested Volume OD 750 nm Protein Amount (Pg) Protein Concentration (diluted) (mg / mL) 50 0.086 4.83 9.66 50 0.069 3.88 7.75 50 0.075 4.21 8.43 100 0.148 8.31 8.31 100 0.150 8.43 8.43 100 0.132 7.42 7.42

[0121] From Table 2, it was deduced that the hydrolyzed extract had a protein content of 8.33 + 0.77 mg / mL or approximately 0.83%. This result confirms that the hydrolyzed extract does indeed include hydrolyzed proteins.

[0122] B. Analysis of the total polyphenol content of the extract by the method using the Folin Ciocalteu reagent

[0123] This analysis was carried out using the extract of Example 1 diluted 1 / 10 in distilled water.

[0124] The determination of total polyphenols was carried out according to the method described in 1965 by Singleton and Rossi using the Folin-Ciocalteu reagent. The Folin-Ciocalteu reagent is a yellow acid consisting of a mixture of phosphotungstic acid (H3PW12040) and phosphomolybdic acid (H3PMO12O40). It is reduced, during the oxidation of phenols, to a mixture of blue oxides of tungsten and molybdenum (Ribereau, 1968). The color produced, whose maximum absorption is at 720nm, is proportional to the quantity of polyphenols present in the sample.

[0125] For this colorimetric assay, a standard curve of the OD, measured at 720 nm, as a function of the quantity of polyphenols was produced.

[0126] The reference compound used in this experiment is gallic acid.

[0127] Preparation of the standard range

[0128] The ingredients for preparing the standard range were as follows: 7.5% Na2CO3 (sodium bicarbonate) solution: Weigh 15g of sodium bicarbonate (sold by Solvay ®) into a 200ml graduated flask and fill with distilled water. Folin-Ciocalteu reagent marketed by Sigma ®: Dilute the reagent to 10% in water. Gallic acid: preparation of the 0.1g / L stock solution: Weigh 0.01g of powdered gallic acid into a 100ml graduated flask and adjust with distilled water.

[0129] The compositions forming the standard range are presented in Table 3.

[0130] [Tables3] Tube No. 1 2 3 4 5 6 Gallic acid concentration (pg / mL) 0 20 40 60 80 100 Gallic acid at 0.1g / L (pL) 0 300 600 900 1200 1500 Distilled water (pL) 1500 1200 900 600 300 0

[0131] Then the standard range was carried out in triplicate according to the protocol below.

[0132] 6 standard solutions were prepared by taking 400 pL from each of tubes 1 to 6 in Table 3 to which 2000 pL of Folin Ciocalteu reagent and 1600 pL of 7.5% Na2CO3 solution were added. After incubation for 30 minutes at 45°C, OD measurements at 720 nm were carried out.

[0133] The DO measurements at 720 nm made it possible to define a curve with the equation: y = 0.0967x - 0.019 with R2 = 0.9982.

[0134] Then the determination of the quantity of total polyphenols in each sample of hydrolysate to be tested (sample tested in triplicate) was obtained by preparing samples to be tested according to the same protocol as that used for the standard range and then by reporting the OD values ​​obtained for the samples to be tested on the standard curve.

[0135] Table 4 presents the results obtained for a dilution of the samples equal to 10. From the standard curve, the OD at 720 nm of each sample was determined and then the concentration of total polyphenols was calculated from the standard curve.

[0136] [Tables4] Sample dilution 1 / 10 OD of sample 1 at 720nm 0.196 OD of sample 2 at 720nm 0.191 OD of sample 3 at 720nm 0.212 Mean 0.200 Standard deviation 0.011 Total polyphenol concentration (mg / L) 2.263

[0137] It can be deduced that the hydrolyzed extract of moabi diluted to 1 / 10 has a total polyphenol content of 2.263 + 0.312 mg / L, i.e. a concentration of 22.63 mg / L + 3.12 mg / L, i.e. 22.63 + 3.12 ppm in the extract according to the invention.

[0138] C. Analysis of the sugar content of the hydrolyzed extract by the Dubois method

[0139] The amount of total sugars (saccharides) was determined by colorimetric assay according to the Dubois method. This method is based on the formation of a chromogenic product of sugar degradation by the action of a strong acid into furfural derivatives. These chromogenic products are then condensed with phenol to obtain an orange-colored chromophore.

[0140] For this colorimetric assay, a standard curve of the OD, measured at 490 nm, as a function of the total quantity of sugars was produced. The reference product used in this method is glucose.

[0141] Then the determination of the total quantity of sugars in each sample of hydrolyzate to be tested was obtained by preparing samples to be tested according to the same protocol as that used for the glucose standard range and then by reporting the OD values ​​obtained for the samples to be tested on the standard curve.

[0142] Preparation of the standard range

[0143] The ingredients for preparing the standard range were as follows: Phenol: marketed by Jansen Chimica ®; H2SO4 97%: marketed by Fluka ®; Water: WATER PLUS marketed by Carlo Erba ®; Anhydrous glucose marketed by Panréac.

[0144] The following solutions were prepared:

[0145] Phenol solution 7.5% (m / v): Dissolve 3.87g of phenol in 51.6mL of WATER PLUS water under a hood.

[0146] Glucose solution at 1 mg / mL: Dissolve 11.1 mg of glucose in 11.1 mL of water WATER PLUS.

[0147] The standard range was carried out in triplicate, according to the protocol presented in Table 5.

[0148] [Tables5] Tube No. 1 2 3 4 5 6 Amount of glucose (pg) 0 10 20 30 40 50 Glucose Img / mL (pL) 0 20 40 60 80 100 Water (pL) 500 480 460 440 420 400 Phenol 7.5% (pL) 250 Close the tubes and mix H2SO4 97% (pL) 1250 Close the tubes and mix

[0149] After a 10-minute break at 30°C, DO measurements at 490 nm were carried out.

[0150] The DO measurements at 490 nm were carried out using a “1240” spectrophotometer from Shimadzu.

[0151] The DO measurements at 490 nm made it possible to define a glucose equation curve: y = 0.0381x with R2 = 0.998.

[0152] Then the samples to be measured were prepared according to the following protocol, after dilution in water between 1 / 100 and 1 / 500.

[0153] Several 500 pL samples of the test sample were introduced into test wells and then 250 pL of 7.5% phenol were added to each test well. The test wells were mixed by inversion, then 1250 pL of 97% H2SO4 was added to each test well. The wells were mixed by vortexing. After a 10-minute pause at 30°C, the OD measurements at 49 nm were carried out.

[0154] Table 6 presents the results obtained for a tested volume of 500 pL. From the standard curve, the sugar concentration of each sample was determined.

[0155] [Tableauxô] Dilution OD 490 nm Amount of glucose (pg) Glucose concentration (diluted sample) (mg / mL) Pure glucose concentration (mg / mL) 200 1.192 31.29 0.063 12.51 200 1.085 28.48 0.057 11.39 200 1.176 30.87 0.062 12.35 500 0.479 12.57 0.025 12.57 500 0.428 11.23 0.022 11.23 500 0.434 11.39 0.023 11.39

[0156] From the table above, it was deduced that the hydrolyzed extract had a sugar content of 11.91 + 0.63 mg / mL or approximately 1.2%.

[0157] The hydrolyzed extract according to the invention comprises approximately 1.2% (m / m) of total sugars, proteins in a content of approximately 0.8% (m / m) and polyphenols in a content of approximately 23 ppm.

[0158] D. Physicochemical characterization by UV spectrum

[0159] The sample of Example 1 was diluted to 1 / 100 in demineralized water. Then the UV-Visible spectrum was carried out using a Jenway® 6705 UV-Visible spectrometer. This spectrum is presented in [Fig.l]: we note the presence of a single peak corresponding to an X wavelength of 230 nm for an absorbance of 2.262.

[0160] Example 2 - Cosmetic activities of the hydrolyzed extract

[0161] To carry out the various measurements, compositions of moabi cake hydrolysate at different concentrations were prepared by diluting the hydrolysate prepared in Example 1.1 above directly in the incubation medium at the target concentration.

[0162] Before carrying out the measurements, the hydrolyzate compositions were stored at room temperature, away from light.

[0163] A. Synthesis of bleomycin hydrolase

[0164] The property of several compositions of moabi cake hydrolysate to increase the synthesis of bleomycin hydrolase was evaluated on normal human epidermal keratinocytes cultured in monolayer culture.

[0165] Normal human epidermal keratinocytes from a 66-year-old donor were cultured in monolayer culture until confluence. Then the keratinocytes were incubated for 48 hours either in the absence of the test extract (control) or in presence of the different compositions of the extract to be tested. At the end of the incubation period, the cells were recovered.

[0166] Intracellular bleomycin hydrolase synthesis was determined in cell lysates using a specified ELISA kit.

[0167] The proteins contained in the cell lysates were quantified by a spectro-colorimetric method known as “Bradford”.

[0168] In Table 7, the results obtained are expressed as 10 12g (pg) of bleomycin hydrolase per 10 3g (mg) of protein, the mean as well as the standard deviation (SD) are also presented. The measurements were carried out in triplicate.

[0169] The level of significance between the "control" and the "reference product" was assessed using a Student's t-test (*: p<0.05).

[0170] The significance level between "control" and "tested compound" was assessed independently for each composition by one-way analysis of variance (one-way ANOVA) followed by a Holm-Sidak test (*: p<0.05).

[0171] [Tables7] Control Moabi meal hydrolysate concentration (%v / v) Reference Ca2+ at 1.5 rnM 0.01% 0.05% 0.2% pg bleomycin Hydrolase / mg protein 58.7 66.2 76.6 145.0 170.3 52.7 62.0 105.8 139.4 172.4 48.6 61.7 105.1 146.7 171.8 Mean 53.3 63.3 95.8*** 143.7*** 171.5*** SD 5.1 2.5 16.6 3.8 1.1 % of control 100 118.7 179.6 269.4 321.4

[0172] *** means: mean significantly different from “control” (p<0.001).

[0173] It appears from this study that the hydrolyzed moabi cake extract increases by significantly the synthesis of bleomycin hydrolase by normal human epidermal keratinocytes in monolayer culture from the concentration 0.05% (v / v). Indeed at the concentration of 0.01% (v / v) the increase is +18.7% compared to the control (p<0.05), at the concentration of 0.05% (v / v) the increase is +79.6% compared to the control (p<0.001) and at the concentration of 0.2% (v / v) the increase is +169.4% compared to the control (p<0.001).

[0174] Natural hydration factors are linked to the activity of bleomycin hydrolase. Indeed, this enzyme is known for its role in the degradation of deiminated filaggrin into acids known for their role in water retention in the horny layer.

[0175] The moabi hydrolyzate according to the present invention therefore has a skin moisturizing effect induced by a physiological action.

[0176] B. Synthesis of hyaluronic acid

[0177] The property of several compositions of moabi cake hydrolyzate to increase the synthesis of hyaluronic acid was evaluated on normal human epidermal fibroblasts cultured in monolayer culture.

[0178] Normal human epidermal fibroblasts from a 68-year-old donor were cultured in monolayer culture until confluence. The fibroblasts were then incubated for 24 hours either in the absence of the test extract (control) or in the presence of the different compositions of the test extract.

[0179] TGF beta (Transforming Growth Factor beta) at 10 ng / mL was used as a reference / positive control for its recognized ability to stimulate the synthesis of intracellular hyaluronic acid.

[0180] At the end of the incubation period, the medium was isolated and measurements were carried out on the incubation medium.

[0181] The amount of hyaluronic acid released into the incubation medium was determined using a specific ELISA kit.

[0182] The proteins contained in the cell lysates were quantified by a spectro-colorimetric method known as “Bradford”.

[0183] As already mentioned, the compositions of moabi cake hydrolysate at different concentrations were prepared by diluting the hydrolysate prepared in Example 1.1 above directly into the incubation medium at the target concentration.

[0184] In Table 8, the results obtained are expressed as 10 9g (ng) of hyaluronic acid per 10 6g (pg) of protein, the mean as well as the standard deviation (SD) are also presented. The measurements were carried out in triplicate.

[0185] The level of significance between the "control" and the "reference product" was assessed using a Student's t-test (*: p<0.05).

[0186] The significance level between "control" and "tested compound" was assessed independently for each composition by one-way analysis of variance (one-way ANOVA) followed by a Holm-Sidak test (*: p<0.05).

[0187] [Tables8] Control Moabi meal hydrolysate concentration (%v / v) Reference TGF beta at 10g / mL 0.03% 0.1% 0.3% ng hyaluronic acid / pg protein 2.5 2.8 2.1 2.3 2.8 2.1 2.5 2.0 2.1 3.1 2.2 3.0 2.2 2.2 2.7 Average 2.3 2.8* 2.1 2.2 2.9* SD 0.2 0.2 0.1 0.1 0.2 % of control 100.0 121.8 93.3 96.3 126.0

[0188] * means: mean significantly different from “control” (p>0.05)

[0189] It appears from this study that the hydrolyzed moabi cake extract significantly increases the synthesis and release of hyaluronic acid by normal human epidermal fibroblasts in monolayer culture at a concentration of 0.3% (v / v). Thus, the hydrolyzed extract according to the invention shows a stimulating effect on the production of endogenous hyaluronic acid in the skin.

[0190] Hyaluronic acid is a molecule known for its anti-aging properties, particularly for filling wrinkles and fine lines, for its smoothing effect on the skin surface and its ability to capture and fix the water present in the epidermis.

[0191] The moabi hydrolyzate according to the present invention therefore has an anti-aging and skin moisturizing effect.

[0192] Example 3 - Cosmetic compositions

[0193] The following cosmetic compositions according to the invention were produced, their components are presented in tables 9 and 10.

[0194] 3.1 Depigmenting cream

[0195] [Tables9] Components g Moabi meal hydrolysate according to example 1 1.4 Vitamin C tetra E (ascorbyl tetraisopalmitate marketed by Ephyla) 0.5 Salicylic acid 0.15 Sodium benzoate 0.5 Xanthan gum (FFPC marketed by Jung-bunzlauer ®) 0.2 Vegetable glycerin (Palmera G995E marketed by Interchimie ®) 3.5 Caprylic / capric triglycerides (DUB MCT 5545) 18 Bentonite / xanthan gum / sodium stearoyl glutamate / citric acid (Frametime CXG marketed by Ephyla) 3.2 Cetostearyl alcohol 50 / 50 1.0 Perfume 0.5 Water 71.05

[0196] The composition was prepared according to the following protocol: the triglycerides and cetostearyl alcohol were mixed at 70°C, then this mixture was cooled to 45°C with stirring. Then, the other ingredients were incorporated at room temperature with stirring with a rotor-stator rotating at 4000 rpm. Stirring was maintained for 5 to 10 minutes after homogenization of the mixture.

[0197] Depigmenting activity

[0198] The depigmenting activity of this composition was evaluated by an independent laboratory authorized to carry out clinical studies on volunteers for the evaluation of cosmetic products, under the supervision of a doctor of pharmacy.

[0199] The depigmenting activity of this composition was evaluated by mexametric measurements according to the calculation of a melanic index using an Antera 3D measuring device integrating a camera and data processing software marketed by the company Miravex.

[0200] Skin coloration at pigment spots was measured by mexametry. This measurement is based on the principle of specific absorption of light by skin melanin at a given wavelength.

[0201] Mexametric measurements are based on the backscattering of diffuse light in tissues. A high-power halogen lamp illuminates the skin via an optical fiber. The measuring probe collects the light scattered by the skin. This light is analyzed by the equipment at the following three wavelengths: green: 568 nm, red: 660 nm, infrared: 880 nm.

[0202] In the present study, the Mexamètre® probe made it possible to determine the melanic index, linked to absorption at 568 nm.

[0203] Volunteers

[0204] The study involved 21 volunteers meeting the following criteria: healthy volunteer; age between 43 and 70 years; volunteer who had already used a product in the same category as the product studied (depigmenting); woman who was not pregnant or likely to be pregnant, woman who was not breastfeeding; volunteer capable of understanding the requirements of the study.

[0205] In addition, the volunteers also had to have at least two pigment spots of at least 5 mm in diameter on the face, neck, décolleté and / or hands without any dermatological lesion on the face, neck, décolleté and / or hands and had to have a normal, non-allergic and non-atopic preliminary clinical examination result and be free from any dermatological lesion on the face, neck, décolleté and / or hands.

[0206] These volunteers also had to not have an incompatible general pathology, nor a progressive dermatological pathology; not follow a treatment based on anti-inflammatories, corticosteroids, antihistamines or any treatment reducing or inhibiting inflammatory or allergic reactions; not have a history of allergies to cosmetic or household products; nor be in a period of exclusion for another study.

[0207] The requirements, throughout the duration of the study, were as follows: attend all visits without having applied any hygiene, care and / or makeup product to the face, neck, décolleté and / or hands; do not expose yourself voluntarily or involuntarily to UV rays (natural or artificial); use a sunscreen cream with a high sun index for outdoor activities; do not change your hygiene and cosmetic habits; do not use new cosmetic products; do not use another cosmetic product of the same class as the product studied (depigmenting); use the product studied as a replacement for your usual product; do not perform any aesthetic or dermatological procedures; do not plan any surgical intervention.

[0208] Protocol

[0209] The study was monocentric (carried out in a single location) and lasted 28 days, i.e. from D1 to D28.

[0210] The application of the product was carried out as follows: twice a day, the volunteer applied a small amount corresponding to a quantity ranging from 0.5 to 1 g of product to the clean skin of the face, neck, décolleté and hands and then massaged until the product was completely absorbed. It was recommended to avoid contact with the eyes and to apply the sunscreen provided before any exposure to the sun.

[0211] AJ1, the protocol consisted of:

[0212] Note in the observation book the current treatments taken by the volunteer; define three sites: treated pigment spot, treated control site, untreated control site; carry out mexametric measurements; take photographs for illustrative purposes of a lentigo; give the volunteer the previously weighed product studied as well as the instructions for use, in particular the dose - a small amount of product - to apply; remind the volunteer of the constraints linked to the study, in particular to carry out the last application the day before the appointment on D28 and to arrive at the visit without having applied any product to the sites examined.

[0213] At D28, the protocol consisted of:

[0214] Check compliance with the protocol requirements; Check observation of applications; Recover the remainder of the product in its initial packaging in order to check consumption; Collect the volunteer's impressions on the cosmetic qualities of the product; Note in the observation book any treatments taken by the volunteer since the last visit; Carry out mexametric measurements on the same sites as on D1; Collect any clinical and / or functional signs of the volunteer; Take standardized photographs under the same conditions as on DL

[0215] Results

[0216] The population analyzed consisted of 21 women aged between 43 and 70 years and with an average age of 61 years with lentigines on the face, neck, décolleté and / or hands.

[0217] The mexametric measurements of the melanic index expressed in absorbance units (AU) were carried out by the Antera 3D device marketed by the company Miravcx.

[0218] [Fig.2] presents the measurements of the melanic index, in average values, between D1 and D28 for the different areas studied: treated pigmented area, treated non-pigmented area, untreated non-pigmented area.

[0219] The statistical analysis carried out on the deltas of the melanic index measurements of each treated area compared to the untreated area (control) at each measurement time, made it possible to show the depigmenting potential of the tested product, both on the treated pigmented area and on the treated non-pigmented area, at D28 compared to DL. The depigmenting potential was confirmed visually by comparing the photos taken at D1 and D28 on the same pigment spots.

[0220] It emerges from this study that the tested composition comprising a moabi hydrolysate according to the invention exhibits depigmenting activity.

[0221] In addition, the volunteers evaluated the cosmetic qualities of the tested composition. This composition received 76% favorable opinions, in particular on the following criteria: the skin is soft, the skin is hydrated, the skin is supple, the tested composition improves the overall appearance of the skin, the tested composition provides a feeling of comfort.

[0222] 3.2 Moisturizing and anti-aging face cream

[0223] [TableauxlO] Components g Phase Demineralized water 55.05 Al Sodium magnesium silicate / xanthan gum / citric acid (Frametime LTX marketed by Ephyla) 0.9 Al Sodium stearoyl glutamate (Amisoft HS-1 IP marketed by Ajinomoto) 0.3 Al Glycerin / ethyl lauroyl arginate, HCl (Aminat G marketed by Seppic) 1 A2 Gluconolactone / sodium benzoate / calcium gluconate (Geogard ultra marketed by Lonza) 1 A2 Propanediol (Propanediol Massocare marketed by Masso) 3 A4 Vegetable glycerin (Palmera G995E marketed by Interchimie ®) 3 A4 Xanthan gum (FFPC marketed by Jung-bunzlauer ®) 0.25 A3 Inulin (Fibrulose F97 marketed by Cosucra) 3 A3 Xylitol (Xivia c marketed by Danisco) 3 A3 Corn starch (Maisita 21-000 marketed by Adetis) 0,5 A3 Bentonite / xanthan gum / sodium stearoyl glutamate / citric acid (Frametime CXG marketed by Ephyla) 4 B Cocoa butter (marketed by Ephyla) 2 B Behenyl alcohol (Lanette 22 marketed by BASF ®) 1,2 B Shea ester (EPHYSTER ECK marketed by Ephyla) 6 B Desert date oil (Desert date oil marketed by Ephyla) 4,5 B Moabi butter (marketed by Ephyla) 5 B , Helianthus annuus seed oil and Protium heptaphyllum resin (HTR1 marketed by Ephyla) 1.5 B Moabi seedcake hydrolysate according to example 1 2 C Vitamin C tetra E (ascorbyl tetraisopalmitate marketed by Ephyla) 2 C Perfume 0.8 C

[0224] The composition of Example 10 was prepared according to the following protocol.

[0225] To prepare phase A, the constituents of phase A1 were mixed at high shear for 12 minutes. This mixture was then successively brought to pH 13 by adding NaOH and then to pH 3.5 by adding lactic acid. Phase A2, then phase A3 and then phase A4 were added successively. The pH was then adjusted to 5 by adding NaOH.

[0226] The ingredients of phase B were melted and then added to phase A with stirring, then phase C was added with stirring.

Claims

Claims

1. Hydrolyzate of moabi or “Baillonella toxisperma” cake, characterized in that it comprises from 0.50 to 1.50% by weight, preferably 0.83% by weight, of proteins relative to the total weight of the hydrolyzate; from 0.50 to 2.00% by weight, preferably 1.19% by weight, of sugars relative to the total weight of the hydrolyzate and from 15 to 30 ppm, preferably 23 ppm, of polyphenols relative to the total weight of the hydrolyzate, said hydrolyzate being capable of being obtained by a preparation process comprising at least the following steps, in this order: - providing moabi seeds; - delipidating the moabi seeds and recovering the cake; - placing the moabi cake in an aqueous phase; - subjecting the cake to at least one hydrolysis step using an alkaline solution at a pH ranging from 13 to 14 for a period ranging from 30 minutes to 4 hours, - adding a weak acid so as to adjust the pH to a value ranging from 4.5 to 5.5;- carry out a solid / liquid separation, - recover the hydrolyzate obtained.;

2. Moabi cake hydrolyzate according to claim 1 characterized in that its visible UV spectrum has a peak at a wavelength X of 230 nm for an absorbance of 2.

262.

3. Hydrolyzate according to any one of the preceding claims wherein, during hydrolysis, the ratio of mass of moabi cake / mass of alkaline solution is between 1 / 12 and 1 / 8 and preferably approximately 1 / 10.

4. Non-therapeutic cosmetic composition characterized in that it comprises at least one hydrolyzate according to any one of claims 1 to 3, preferably in a content ranging from 0.001 to 30% by weight and preferably from 0.1 to 20% by weight relative to the total weight of the composition.

5. Cosmetic, non-therapeutic composition according to the preceding claim comprising ascorbyl tetraisopalmitate, preferably in an ascorbyl tetraisopalmitate / hydrolyzate ratio ranging from 1 / 1 to 1 / 10 and advantageously approximately 1 / 3.

6. A non-therapeutic cosmetic composition according to claim 4 or 5 comprising, in a cosmetically acceptable medium, at least one cosmetic agent selected from humectants, thickeners, texturizing agents, emulsifiers, dispersing agents, foaming agents, emulients, preservatives, colorants, plant extracts, plant fibers, minerals, pH correcting agents, active ingredients and perfumes.

7. Non-therapeutic cosmetic composition according to any one of claims 4 to 6, characterized in that it is intended to be applied to the skin.

8. Cosmetic, non-therapeutic use of a hydrolyzate according to any one of claims 1 to 3 or of at least one cosmetic composition according to any one of claims 4 to 7 as a moisturizing active ingredient for the skin.

9. Cosmetic, non-therapeutic use of a hydrolyzate according to any one of claims 1 to 3 or of at least one cosmetic composition according to any one of claims 4 to 7 as an active ingredient for preventing and / or reducing the signs of skin aging, in particular loss of skin elasticity, alteration of the skin barrier function, the appearance of wrinkles and / or fine lines.

10. Cosmetic, non-therapeutic use of a hydrolyzate according to any one of claims 1 to 3 or of at least one cosmetic composition according to any one of claims 4 to 7 as an active ingredient for whitening and / or lightening and / or depigmenting the skin, in particular for reducing the size of brown pigmentation spots, attenuating or even eliminating brown pigmentation spots, or preventing, reducing and / or treating an alteration in the complexion of the skin.

11. Cosmetic, non-therapeutic process for treating the skin, comprising at least one step of applying to the skin a hydrolyzate according to any one of claims 1 to 3 or a cosmetic composition according to any one of claims 4 to 7.

12. Cosmetic, non-therapeutic process according to claim 11 intended to maintain or improve the hydration of the skin.

13. Cosmetic, non-therapeutic process according to claim 11 intended to prevent and / or reduce the signs of skin aging, in particular the loss of elasticity of the skin, the alteration of the barrier function of the skin, the appearance of wrinkles and / or fine lines.

14. Cosmetic, non-therapeutic process according to claim 11 intended to depigment, lighten and / or whiten the skin.